Navigation Links
New Drug Boosts 'Good' Cholesterol in Study Patients
Date:9/13/2011

TUESDAY, Sept. 13 (HealthDay News) -- A treatment currently being studied may prevent progression of atherosclerosis, a condition caused by the build-up of plaque in artery walls that can lead to heart attack, according to new research.

In conducting the study, published in the Sept. 12 issue of The Lancet, researchers followed 130 patients with atherosclerosis who were randomly assigned to be treated with either the experimental heart drug dalcetrapib, or an inactive placebo over the course of two years. In the double-blind study, neither the researchers nor the patients knew who was taking the heart drug and who was taking the placebo.

While statin drugs are commonly used to lower LDL or "bad" cholesterol to reduce the risk of coronary artery disease, dalcetrapib raises HDL or "good" cholesterol in order to reduce the risk, the researchers explained.

To determine the efficacy of dalcetrapib, the researchers used non-invasive imaging technology. Through MRI, the researchers found the patients on dalcetrapib had a 31 percent increase in "good" HDL cholesterol levels. Additional PET/CT scans showed that inflammation levels in the carotid artery of patients were significantly reduced only among those taking dalcetrapib. The carotid arteries are responsible for supplying oxygenated blood to the head and neck.

In a different study, a drug in the same class designed to raise HDL levels was tied to an increase in death linked to vascular inflammation, but the researchers did not find an increase in such inflammation with dalcetrapib.

"This milestone study shows that MRI and PET/CT are highly useful in assessing the safety and efficacy of dalcetrapib, and that this novel therapy may address a significantly unmet need in cardiovascular disease," said lead study author Zahi A. Fayad, a professor of radiology and medicine in the cardiology division at Mount Sinai School of Medicine and the director of its Translational and Molecular Imaging Institute, in a Mt. Sinai news release.

"We are excited about the results obtained in this trial, which could have a great impact on the treatment of patients with cardiovascular disease," said Fayad, who disclosed receiving financial compensation as a scientific advisory board member from the study's sponsor, Hoffmann-La Roche, whose holding company makes dalcetrapib.

Fayad noted imaging technology could be a vital tool for evaluating other treatments for heart disease.

More information

The U.S. National Library of Medicine has more about atherosclerosis.

-- Mary Elizabeth Dallas

SOURCE: Mount Sinai Hospital, news release, Sept. 12, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. TNF Treatment for Rheumatoid Arthritis Boosts Skin Cancer Risk
2. Regular Exercise Boosts the Brain, Too
3. Yoga boosts stress-busting hormone, reduces pain: York U study
4. Stopping Daily Aspirin Boosts Heart Attack Risk: Study
5. Study: Potassium Boosts Heart Health, Salt Harms It
6. Even One Glass of Beer, Wine Boosts Car Crash Risk: Study
7. Mystery ingredient in coffee boosts protection against Alzheimers disease
8. On-the-Job Activity Boosts Americans Exercise Levels
9. Weight Loss in Heavy, Obese Women Boosts Vitamin D Levels
10. Losing more than 15 percent of body weight significantly boosts vitamin D levels in overweight women
11. Tai Chi Prevents Falls, Boosts Mental Health in Seniors: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Drug Boosts 'Good' Cholesterol in Study Patients
(Date:5/26/2017)... ... May 26, 2017 , ... Leading CEOs from biotech, ... 30th and 31st at The Four Seasons Hotel Boston. , The Boston ... sciences, offering exclusive access to key decision makers who influence deal making and ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... Amir Qureshi, ... System, a powerfully versatile, patient-centric spinal cord stimulation system. The Nuvectra™ Algovita SCS System ... “We are pleased to be the first in Arkansas to introduce the most powerful ...
(Date:5/26/2017)... ... ... A new analysis of community health data reveals that four out of the ... the average cost of healthcare rising and the U.S. senior population expected to double ... of where they live. An annual 2017 report looked at a variety of community ...
(Date:5/26/2017)... Nevada (PRWEB) , ... May 26, 2017 , ... ... produce the first ever copper, antimicrobial, mesh back 24/7 task chair specifically designed ... conference applications. “We are thrilled to partner with Cupron® to provide customers ...
(Date:5/26/2017)... ... 26, 2017 , ... After raising nearly $30,000 on Kickstarter , about ... available at a discounted crowdfunding price on Indiegogo . , “Along with creating ... wanted to bring a fidget toy to the market that was made of superior ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... Hologic, Inc. (Nasdaq: HOLX ) ... second quarter ended April 1, 2017 .   GAAP ... compared to the prior year period as the sale ... gain, while non-GAAP diluted EPS of $0.50 increased 6.4%.  ... constant currency terms.  Excluding the effects of blood screening ...
(Date:5/10/2017)... 10, 2017 Radiology has become the number ... have also spiraled to the number one ranking as ... than ever before as the most complete and reliable ... with lower back pain an MRI may confirm a ... pain, resulting in entirely different treatment protocols.  In these ...
(Date:5/9/2017)... WASHINGTON , May 9, 2017  Demonstrating ... the board of directors for the Pharmaceutical Research ... criteria for membership. Biopharmaceutical companies will now have ... in order to be eligible to join PhRMA. ... criteria, the board is sending a clear message ...
Breaking Medicine Technology: